Search

Displaying results 4191 - 4200 of 7603 in total
  1. Drug

    Plozasiran

    go.drugbank.com/drugs/DB18997
    ApprovedInvestigational

    Plozasiran (ARO-APOC3) is a small interfering RNA (siRNA) that degrades apolipoprotein C-III (apoC-III) mRNA by RNA interference. Plozasiran contains a covalently linked ligand containing three N-acetylgalactosamine (GalNAc) residues to ...

  2. Drug

    Ancremonam

    go.drugbank.com/drugs/DB19710
    Investigational

    Ancremonam is under investigation in clinical trial NCT03377426 (LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Urinary Tract Infection (cUTI)).

  3. Drug

    CT-011

    go.drugbank.com/drugs/DB05916
    Investigational

    CT-011 is a humanized monoclonal antibody directed against a B7 family-associated protein, in patients with advanced haematological malignancies. It is directed against human PD-1 (programmed cell death 1; PDCD1), with immunomodulating a...

  4. Drug

    Cefodizime

    go.drugbank.com/drugs/DB13470
    Investigational

    Cefodizime is a third generation cephalosporin with a broad spectrum of antibacterial activity.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  5. Drug

    Ketazolam

    go.drugbank.com/drugs/DB01587
    ApprovedWithdrawn

    Ketazolam is not approved in Canada or America.

  6. Drug

    Midodrine

    go.drugbank.com/drugs/DB00211
    ApprovedInvestigational

    An ethanolamine derivative that is an adrenergic alpha agonist. It is used as a vasoconstrictor agent in the treatment of hypotension.

  7. Drug

    TL-895

    go.drugbank.com/drugs/DB16471
    Investigational

    TL-895 is under investigation in several clinical trials for its safety and efficacy in various conditions: NCT04419623 (completed, COVID-19 in cancer patients), NCT02825836 (active, not recruiting, B

    Categories: Experimental Unapproved Treatments for COVID-19
  8. Drug

    AT1022

    go.drugbank.com/drugs/DB04995
    Experimental

    AT1022 is a hydromorphone skin patch designed to provide rapid and sustained delivery of a potent opiate for the management of severe pain. … AT1022 incorporates PassPort(TM) system, developed to deliver protein and peptide drugs, small-molecule drugs, genes and vaccines across the skin for local and systemic effect.

  9. Drug

    Reteplase

    go.drugbank.com/drugs/DB00015
    ApprovedInvestigationalWithdrawn

    Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. ...

    Products: RAPILYSIN 10 U IV ENJ. ICIN STERIL LIYOFILIZE TOZ ICEREN FLAKON, 2 ADET
  10. Drug

    Rilapladib

    go.drugbank.com/drugs/DB05119
    Investigational

    Rilapladib is the third genomics-derived small molecule drug arising from the Human Genome Sciences-GlaxoSmithKline collaboration to enter clinical development. It is a lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor. Lp-PLA2...